Mercedes Launches 2025 G-Class Electric with Four Motors and Revolutionary Tank Turns 
If plastic manufacturing goes up 10%, plastic pollution goes up 10% – and we’re set for a huge surge in production 
Supreme Court appears open to Starbucks’ claims in labor-organizing case 
Asahi Kasei to Build EV Battery Plant in Canada to Supply Key Parts to Honda Motor 
Boeing Experiences Quarterly Revenue Drop Amid Production Challenges, Beat Expectations 
New Study Reveals Coke, Pepsi, and Nestle as Top Plastic Polluters 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
Hybe Accuses ADOR Subsidiary’s CEO of Breach of Trust 
Whirlpool’s Stale Demand Led to 1,000 Job Cuts in the US 
Why is the London Stock Exchange losing out to the US 
Family farms are fast disappearing: our research shows how young generations can take them up successfully 
GS25 Launches Limited-Edition Makgeolli ‘Seoul Silver’ in Korea 
Hermes Surpasses Expectations with a 17% Surge in First-Quarter Sales 
Tesla Nears FSD Licensing Deal with Major Automaker, Hits 1.3 Billion Milestone 
LATAM Airlines Abandons Plans to Acquire Boeing B737 Planes Amid Gol Bankruptcy 
How marketing classes can rescue ‘ugly produce’ from becoming food waste 
IBM Acquires HashiCorp, Giving Its Hybrid-Cloud Business a Boost 
LOS ANGELES, April 27, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD) concerning possible violations of federal securities laws between July 7, 2016 and April 9, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired the Company’s shares during the Class Period should contact the firm prior to the June 19, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that the Company’s New Drug Application (“NDA”) submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the Food & Drug Administration’s potential approval of the NDA. When this information was released, the Company’s stock price decreased materially, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
